TOMZ News & Events

TOMI Environmental Solutions announced the sale of a Custom Engineered System, CES, in the United Kingdom, U.K., to an international pharmaceutical manufacturing organization. The system is being delivered as part of a bespoke, modular cleanroom platform designed, engineered, and validated by Total Clean Air, TCA. SteraMist iHP has been fully integrated into TCA's modular cleanroom architecture, marking the first deployment of iHP technology within TCA's modular platform.

TOMI Environmental Solutions announced the purchase of its SteraMist Hybrid System within a new facility of a private research university on the East Coast. Elissa J. Shane, Chief Operating Officer of TOMI Environmental Solutions states, "The SteraMist Hybrid System was the ideal solution for this deployment, and we are discussing further installations within the university. The fact that this research university has integrated this system to meet their stringent operational needs validates iHP as the superior, reliable choice for high-stakes medical product sterilization."

Tomi Environmental Solutions announced that a cell and gene therapy manufacturer has adopted SteraMist ionized hydrogen peroxide technology for its commercial-scale facility. The client has invested in multiple SteraMist systems to facilitate surface treatment and automated room fogging. To provide a transition to commercial production, the partnership includes Tomi's standard operating procedure development package and installation and operational qualification package.

TOMI Environmental Solutions announced announced it has received a significant signed purchase contract including a purchase order valued at approximately $500,000 from one of the world's largest and most respected biopharmaceutical companies. This order is for the complete integration of TOMI's SteraMist Integrated Systems, SIS, platform into critical manufacturing infrastructure. The purchase contract specifically mandates the use of SteraMist iHP technology into passthrough fill boxes. These systems will be deployed across two separate areas in the global biopharma company specializing in the discovery, development, and manufacture of innovative medicines.